Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients

What Was Tested

This randomized controlled trial paper looks at Exenatide and Glucagon.

To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Patients received a meal test/tracer study (MTT) to measure endogenous glucose production (EGP), rate of oral glucose appearance (RaO), insulin secretion rate (ISR), ß-cell function, hepatic insulin resistance (HIR) and adipose tissue insulin resistance (AT-IR) and insulin sensitivity (IS).

How the Study Was Run

The design is described as randomized.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Adipose Tissue, Blood Glucose, Exenatide, Fasting, Gastric Inhibitory Polypeptide, Glucagon and Glucagon-Like Peptide 1.

The authors tagged it with the keywords GLP-1 receptor agonist, endogenous glucose production, glucose metabolism, insulin resistance, insulin secretion and lipolysis.

What This Means in Plain Language

The paper is a randomized study of Exenatide and Glucagon.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page and the Glucagon compound page, all human trials.